Clal Bio unit plans $75m IPO in the U.S.
The shares represent 24.5% of the ownership in the company.
MediWound, a Clal Biotechnology subsidiary that develops products for the treatment of severe burns and wound management, is in the process of trying to raise $75 million through an offering of 5 million shares of the company.
register with haaretz
Like us on Facebook and get articles directly in your news feed